EDA and neoplasm: These data might indicate that the therapeutic efficacy of NK+mAb9.2.27 combination treatment was mediated by increased recruitment of ED1+ CCR2low macrophages, which then differentiate into (or activate) ED1+ ED2lowMHCIIhigh microglia in the tumor microenvironment.